COMP <GO>
MLYS vs URGN // RETURN ON INVESTED CAPITAL (ROIC)
Mineralys Therapeutics Inc. (NASDAQ) VS. UroGen Pharma Ltd. (NASDAQ) • 15-METRIC TALLY: MLYS 4
— URGN 0
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MLYS
LAST: $15.55 (-14.47%) • MKT CAP: $1.61B
roic
-28.40%
LAST: $34.36 (+5.01%) • MKT CAP: $1.60B
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MLYS VS. URGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MLYS | URGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -28.40% | -35.00% | +6.60 | MLYS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.58% | -9.94% | +2.36 | MLYS | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 21.40% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.9 | 29.7 | +7.20 | MLYS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.61B | $1.60B | $7.9M | MLYS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MLYS REV | URGN REV | MLYS GROSS % | URGN GROSS % | MLYS FCF | URGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $477.7M | $109.8M | — | 88.7% | -$142.4M | -$162.7M |
| FY 2024 | $538.7M | $90.4M | — | 90.2% | -$166.3M | -$97.1M |
| FY 2023 | $237.0M | $82.7M | — | — | -$81.2M | -$76.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MLYS // BETA —
URGN // BETA —